The fight for research dollars

FOR Elizabeth Foley, advances in research into chronic myeloid leukaemia were agonisingly too slow to save the life of her husband, who died at 32, just years before Gleevec was made available.

Now, as CEO of Research Australia, the independent peak body representing the health and medical research sector, she helps to dictate the pace and strategic direction of such advances.

It would perhaps be understandable if Ms Foley’s personal heartache (she also lost a brother to thymoma,